Catheter Precision, Inc. · AMEX:VTAK
Catheter Precision — Ra Medical Systems — Investor Presentation (March 2021)
20 slides from Catheter Precision's investor presentation, Mar 8, 2021
Slide 1: Corporate Presentation March 2021
Ra Medical Systems, Inc. NYSE American: RMED Corporate Presentation March 2021 1 Exhibit 99.1
Slide 2: Disclaimer
Disclaimer Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of Ra Medical Systems, Inc. (the “Company”) and involve known and unknown risks, uncertainties and othe
Slide 3: Opportunity: Proven, Platform Technology
Opportunity Proven, Platform Technology 308 nanometer excimer laser system with Dermatology and Peripheral Artery Disease (PAD) applications PHAROS technology treats chronic skin diseases with a reusable handpiece DABRA technology leverages same basic laser platform to treat PAD with single-use cath
Slide 4: DABRA Overview
DABRA Overview Near-term focus is execution of 1) engineering programs to enhance DABRA catheter deliverability with next-generation products and 2) an FDA-approved clinical study to obtain an atherectomy indication Launch next-generation DABRA products targeting office-based labs segment of PAD mar
Slide 5: DABRA Targets Large PAD Market
DABRA Targets Large PAD Market 2 The Sage Group 2014 3 Millennium Research Group December 2020 4 FDA-approved atherectomy indication study enrolling in US 1 The Sage Group 2013
Slide 6: DABRA Pivotal Study
DABRA Pivotal Study DABRA effectiveness as measured by successful crossing of target lesion 94% The pivotal study formed the basis of our May 24, 2017 510(k) clearance. For information on how we defined device-related SAEs for purposes of our pivotal study, see https://clinicaltrials.gov/ct2/show/st
Slide 7: FDA-Approved IDE Atherectomy Indication Study
FDA-Approved IDE Atherectomy Indication Study Primary safety endpoint: The incidence of 30-day Major Adverse Events (MAEs) as adjudicated by the Clinical Events Committee: All-cause mortality Unplanned major target limb amputation (at or above the ankle) and/or Clinically driven target limb revascul
Slide 8: DABRA Engineering Programs
DABRA Engineering Programs Extend shelf life of DABRA catheters Root causes of shelf-life limitations identified in 2020 Mitigation plans are being implemented with in-house accelerated aging data supporting 6-month or greater shelf life Next-gen DABRA catheter with improved deliverability and robus
Slide 9: Intellectual Property Portfolio
Intellectual Property Portfolio Patents covering several aspects of the laser systems and delivery device The Company believes that its intellectual property comprises novel and useful inventions that can be protected by patents, and as such, has filed patent applications directed to innovative meth
Slide 10: PHAROS Overview
PHAROS Overview Focused on commercial execution during COVID with a new sales leader who joined in Q4 2020 Strategy to grow business post-COVID in capital efficient manner with commercial footprint expansion and laser system improvements
Slide 11: PHAROS Treats Chronic Skin Disease
PHAROS Treats Chronic Skin Disease 1 National Psoriasis Foundation & JAMA Dermatology 2 National Library of Medicine 3 National Eczema Association
Slide 12: Results of Operations
Results of Operations * Adjusted EBITDA is a non-GAAP measure and is calculated as net profit (loss) excluding interest income (expense), income tax expense and certain recurring, non-cash charges such as depreciation and amortization of long-lived assets as well as stock-based compensation expenses
Slide 13: Financial Position
Financial Position We define working capital as current assets minus current liabilities Cash management remains a priority
Slide 14: Recent & Future Milestones
Recent & Future Milestones *Unable to accurately predict atherectomy indication study enrollment due to COVID-19 impact
Slide 15: Turnaround Opportunity With Focus On Execution
Turnaround Opportunity With Focus On Execution Proven, Platform Technology 308 nanometer excimer laser system with Dermatology and Peripheral Artery Disease (PAD) applications PHAROS technology treats chronic skin diseases with a reusable handpiece DABRA technology leverages same basic laser platfor
Slide 16: Appendix
Appendix
Slide 17: R&D and Manufacturing Facility
R&D and Manufacturing Facility Carlsbad, CA 41,000 sq. ft. in Carlsbad, CA with three controlled environments Sizable capacity for laser and catheter production Fully capitalized with all equipment owned ISO13485 certified, FDA and CA state inspected Laser Assembly Controlled Environments
Slide 18: Management Team
Management Team Will McGuire ‘Andrew Jackson Dan Horwood Chris Folk, PhD ‘Al Memmoto Tiah Reppas SR Medical Chief Executive Officer Chief Financial Officer 25 years med:-tech experience, including COO of Spectranetics which was. ‘acquired by Philips for >$2 bilon and CEO of Atheromed, a venture capi
Slide 19: Board of Directors
Board of Directors ‘Martin Colombatto Chairman. Former VP and General Manager af Broadcom William Enquist Former President of Global Endoscopy of Stryker Will MeGuire Chiet Executive Oficer, Ra Medical Former CEO Second Sight, former executive at Covidien, AtheroMed, Spectranetics Richard Mejia Form
Slide 20: Reconciliation of Net loss to Adjusted EBITDA
Reconciliation of Net loss to Adjusted EBITDA
Ra Medical Systems — Investor Presentation (March 2021) on 6ix